200 related articles for article (PubMed ID: 33045316)
1. Phase 1 Study of Low-Dose Fractionated Whole Abdominal Radiation Therapy in Combination With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer (GCGS-01).
Ngoi NYL; Heong V; Tang JI; Choo BA; Kumarakulasinghe NB; Lim D; Low M; Lim SE; Lim YW; Leong YH; Tseng M; Tong PSY; Ilancheran A; Low JJH; Ng J; Thian YL; Koh V; Tan DSP
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):701-711. PubMed ID: 33045316
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial.
Moreno V; Barretina-Ginesta MP; García-Donas J; Jayson GC; Roxburgh P; Vázquez RM; Michael A; Antón-Torres A; Brown R; Krige D; Champion B; McNeish I
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34893524
[TBL] [Abstract][Full Text] [Related]
3. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum.
du Bois A; Lück HJ; Buser K; Meerpohl HG; Sessa C; Klaassen U; Meden H; Bochtler H; Diergarten K
Eur J Cancer; 1997 Mar; 33(3):379-84. PubMed ID: 9155520
[TBL] [Abstract][Full Text] [Related]
4. Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer.
Linch M; Stavridi F; Hook J; Barbachano Y; Gore M; Kaye SB
Gynecol Oncol; 2008 Apr; 109(1):27-32. PubMed ID: 18262259
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.
Le T; Hopkins L; Baines KA; Rambout L; Al Hayki M; Kee Fung MF
Gynecol Oncol; 2006 Jul; 102(1):49-53. PubMed ID: 16375951
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
[TBL] [Abstract][Full Text] [Related]
7. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.
; Markman M; Blessing J; Rubin SC; Connor J; Hanjani P; Waggoner S
Gynecol Oncol; 2006 Jun; 101(3):436-40. PubMed ID: 16325893
[TBL] [Abstract][Full Text] [Related]
10. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
Rose PG; Blessing JA; Mayer AR; Homesley HD
J Clin Oncol; 1998 Feb; 16(2):405-10. PubMed ID: 9469322
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients.
Kaern J; Baekelandt M; Tropé CG
Eur J Gynaecol Oncol; 2002; 23(5):383-9. PubMed ID: 12440808
[TBL] [Abstract][Full Text] [Related]
13. Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.
Vergote I; von Moos R; Manso L; Van Nieuwenhuysen E; Concin N; Sessa C
Gynecol Oncol; 2018 Sep; 150(3):471-477. PubMed ID: 30060963
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of 96-hour paclitaxel infusion plus accelerated radiotherapy of unrespectable head and neck cancer.
Machtay M; Aviles V; Kligerman MM; Treat J; Weinstein GS; Weber RS; Mirza N; Chalian AA; Rosenthal DI
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):311-5. PubMed ID: 10760424
[TBL] [Abstract][Full Text] [Related]
15. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer.
Leiser AL; Maluf FC; Chi DS; Sabbatini P; Hensley ML; Schwartz L; Venkatraman E; Spriggs D; Aghajanian C
Int J Gynecol Cancer; 2007; 17(2):379-86. PubMed ID: 17362316
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of weekly docetaxel infusion and concurrent radiation therapy for head and neck cancer.
Suzuki M; Nishimura Y; Nakamatsu K; Kanamori S; Koike R; Kawamoto M; Mori K
Jpn J Clin Oncol; 2003 Jun; 33(6):297-301. PubMed ID: 12913084
[TBL] [Abstract][Full Text] [Related]
18. Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer.
Ghamande S; Lele S; Marchetti D; Baker T; Odunsi K
Int J Gynecol Cancer; 2003; 13(2):142-7. PubMed ID: 12657114
[TBL] [Abstract][Full Text] [Related]
19. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Coleman RL; Handley KF; Burger R; Molin GZD; Stagg R; Sood AK; Moore KN
Gynecol Oncol; 2020 May; 157(2):386-391. PubMed ID: 32037195
[TBL] [Abstract][Full Text] [Related]
20. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
